Mentions
Extended reach
Total likes
Video views
AI synopsis
This collection of discussions demonstrates high interest, with many posts citing the study as evidence of serious gastrointestinal risks like bowel obstruction and pancreatitis, often emphasizing their personal or clinical significance. The tone varies from cautious skepticism to alarmed concern, reflecting the potential impact of the publication on drug safety perceptions and health decisions.
Most discussions acknowledge the risks identified in the publication, with some expressing concern or skepticism about the severity and frequency of side effects.
Participants show high curiosity, frequently referencing specific risks like pancreatitis and bowel obstruction, indicating a strong focus on the publication's findings.
Several posts delve deeper, mentioning related studies, personal experiences, or calling for further investigation, reflecting significant engagement.
The discussions highlight potential health risks and controversy surrounding these medications, suggesting that the publication could influence clinical practices and public perception.
More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss" https://t.co/svOtyp5yrZ
減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 2023 Oct 5:e2319574. Online ahead of print. PMID:37796527 https://t.co/bpOG8mLOMk
(282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGLP-RAは膵炎9.09倍、腸閉塞4.22倍のリスク。胆道疾患は関連無し https://t.co/MylAlvJyfr
@kevinnbass Ozempic is temporary and disappears once the drug is stopped (requiring the patient to become a permanent customer). Ozempic has a variety of common and severe side effects due to it paralyzing the digestive tract. https://t.co/9475IBd0Ep
Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty obstruction & perforation. These drugs have been shown to massively increase risk of bowel obstruction and other GI problems. https://t.co/CGY7hLCnCG
Join Dr McDougall and Mary McDougall as they explore recent studies on obesity, health secrets, and the Potato Reset diet, providing insights into managing obesity and improving health.
This video examines the effectiveness and side effects of semaglutide versus liraglutide in adults with obesity. Findings from a 68-week clinical trial indicate significant differences in weight management outcomes and…
Studies have found increased risks of gastrointestinal adverse events with GLP-1 agonist use in patients with diabetes. The research compares the effectiveness and side effects of semaglutide vs liraglutide for weight…
RT @C_A_G0101: 3/3 https://t.co/XjPhSvBhlr
3/3 https://t.co/XjPhSvBhlr
@ManicZebra @AzureXiong Yup, here’s one: https://t.co/b28MGGRZgp
8. Bowel obstruction Likely real— so infrequent it’s within the statistical noise. https://t.co/ORQHkapIo0
@Blaspie @cremieuxrecueil 1. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (Sodhi M et al., 2023, JAMA): Increased risk of pancreatitis (9x), bowel obstruction (4.2x), gastroparesis (3.7x) in weight loss users; long-term GI complications
@r0b0t_sp1der @Indy_0_22 @esjesjesj @peterrhague @GorehamKeith That dickhead is just lying. It’s a risk of about 0.01%, the same as ibuprofen or birth control https://t.co/RJ4vTYfXul
@GorehamKeith @peterrhague That’s a lie. The figure is about 0.05% or less than 1 in 2000, and the risk factors for that are well known. It’s about the same risk as that from ibuprofen or birth control https://t.co/RJ4vTYfXul
@endocrinorosero “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss” publicado en JAMA en 2023 es una carta de investigación breve pero relevante, que explora eventos gastrointestinales sin embargo lleno de errores abro hilo..
@odavila_intmed Es porque te falta revisar mejor : Risk of Gastrointestinal Adverse Events Associated With Glucagon‑Like Peptide‑1 Receptor Agonists for Weight Loss DOI: 10.1001/jama.2023.19574
RT @BiblicalRx: Dr. Marcum shares 3 Biblical Prescriptions for weight management. https://t.co/ofSZPXQozo Studies Cited: https://t.co/CwE…
@mstotty88 How do you know it is GS pancreatitis? GLP1 is associated with pancreatitis on its own (and not associated with biliary complications). Perhaps just bystander stones and GLP1-induced panc? (Would still take out GB, just not prophylactically). https://t.co/WCGslxI4l2
Problemas intentinales graves: https://t.co/QC1kS3PU44 Achica el miocardio: https://t.co/o5qYSHQh7V Aumenta el riesgo de neuropatía óptica: https://t.co/MpyZfA8RoE + https://t.co/7lwa4eObe5 Etcetc. Hay mucha propaganda a favor hoy en día, pero banquen unos años.
GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/IAvoYSie51
@seanspicer @NYPostOpinion @ivimhealth the glp-1 injections are not safe. There are risks involved. I have seen veterans who used these drugs which resulted in pancreatitis and cancer. Another gained weight back plus another 30% of weight once they quit the glp-1. https://t.co/nmP9FQAylI.
@JasnaEkat @Timcast There are a lot of problems with Ozempic. There are far safer ways to control weight and T2 diabetes. "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss" https://t.co/EKovDoQ1kt https://t.co/SPP7ypQxQh
Dr. Marcum shares 3 Biblical Prescriptions for weight management. https://t.co/ofSZPXQozo Studies Cited: https://t.co/CwEIe82Y1U #weightmanagement #weightlossprogram #weightloss #healthyweight #bodycomposition #biblicialprescriptionsforlife #drmarcum #heartwiseministries
https://t.co/X3qmIQUHYC https://t.co/r4d8EZUoVW Heart shrinkage, stomach paralysis, eye problems, these are all side effects that doesn't exist in a certain unsubstitutable nutrient that works 3, 4 times more better in naturally inceeasing GLP-1. https://t.co/GBFPCgvItZ
Het gebruik van GLP-1-agonisten vergeleken met bupropion-naltrexon werd geassocieerd met een verhoogd risico op pancreatitis, darmobstructie en gastroparese. #ozempic https://t.co/m0xPZgUy0p https://t.co/b4awkR2gMi
@BohoHobbit88 shared this with us: @DocSteve51 @thejacobdean_ @hodgetwins @RealAlexJones GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/kl7TmDeaBO https://t.co/u46NOX5F3q
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
RT @joshg99: Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty o…
Somebody I know lost over 100 lbs on a GLP-1 agonist like Ozempic. He just had to have 1/3 of his colon removed due to nasty obstruction & perforation. These drugs have been shown to massively increase risk of bowel obstruction and other GI problems. https://t.co/CGY7hLCnCG
@elonmusk @WallStreetMav https://t.co/tiL9EO7rW8
@kevinnbass https://t.co/ldff1HGP9v
RT @kacdnp91: @ElleBee617 @elonmusk https://t.co/ldff1HGhjX
@stillgray @elonmusk https://t.co/kt0Lg2rFqc
RT @kacdnp91: @ElleBee617 @elonmusk https://t.co/ldff1HGhjX
@ElleBee617 @elonmusk https://t.co/ldff1HGhjX
@elonmusk The side effects of GLP-1 inhibitors need much more investigation first. https://t.co/tiL9EO7rW8
@naval @elonmusk https://t.co/4WZSCgLQH1
RT @JohnBur58169900: @kevinnbass Ozempic is temporary and disappears once the drug is stopped (requiring the patient to become a permanent…
@kevinnbass Ozempic is temporary and disappears once the drug is stopped (requiring the patient to become a permanent customer). Ozempic has a variety of common and severe side effects due to it paralyzing the digestive tract. https://t.co/9475IBd0Ep
RT @ElizabethRN321: @mattstaton @SCarusetta https://t.co/bUEzX1Kp5i
@mattstaton @SCarusetta https://t.co/bUEzX1Kp5i
@AviBittMD Just stop. https://t.co/yZ5I86aYLf https://t.co/Vs0NsRSBiN
@DrNadolsky Fact check: True
@AliceFromQueens ... But since you insist: https://t.co/DDfmVuGRiO I'm willing to take better/more recent adverse incident data if you have it.
@Anonym64382296 @Andre_AGTC @Quantumup1 Dude, it’s a *well* established side effect of GLP-1s… But if you really want me to google it for you… https://t.co/jt9YUNZyX9 https://t.co/y13O1l0N8O https://t.co/GfIVPmx2T6
@AndrewJWHaynes @TLNewmanMTL Adverse events are still pretty rare as acknowledged in the paper. Obesity has its own health risks and doctors prescribing it for the treatment of obesity will be discussing the risk trade-offs with their patients. https://t.co/MvUb9LDz8b
@Maymoune @psy4ist Je peux vous assurer que je ne m'amuserais pas à inventer quoi que ce soit, pourquoi mettre en doute ce que j'ai observé ? Pour les risques : https://t.co/12a5tnSbmf
@NiomiJA @newstart_2024 >gastro paralysis Plausible, although the study didn't compare different types of incretin mimetics. Pretty rare - maybe 1 in 1000 would be excluded from taking the medication on this ground. https://t.co/qXYl0zOBtt
(JAMA) Efectos adversos gastrointestinales de los aGLP1 (liraglutida y semaglutida) vs. bupropion-naltrexona en pacientes obesos (sin DM): ↑riesgo de pancreatitis, gastroparesis y obstrucción intestinal https://t.co/xWrcshrl7b Est. observ
GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/wMBpX8VlV8
RT @keisuke4713: 減量目的GLP-1受容体Agonist 胃腸有害事象risk https://t.co/L3YmIbmg1p PharMetrics Plus database 胆道疾患発生/千人年 semaglutide11.7 liraglutide18.…
@Sir_Literal @ashawolves @GobbiWasabi @LucaGuadagnegro @agraybee From October 5, 2023 Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss JAMA Network Open's Journal Impact Factor is 10.5, the third highest ranking among general medicine open access journals.
GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/5HzV6PnmVf
GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/pz7uK9wDpN
@GuillaumeBarucq La science, rien que la science et les publications scientifiques. Ça ne date pas d'aujourd'hui, ex : https://t.co/LQtzFeq8zg
Just what we need: More people with GI issues
RT @cjbakermd: Ozempic, aka the "skinny jab" is all the rage, and makes a fortune for Novo Nordisk. But pancreatitis is no joke. Will it b…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroenterology | JAMA | JAMA Network https://t.co/Jq6eR38V1B
RT @sanoysalvoblog: Riesgo de efectos adversos gastrointestinales (pancreatitis, gastroparesia y obstrucción intestinal) asociados al uso d…
read below: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/Z0T0HZhGpt https://t.co/WcTRrfbG9s
@rubyowaves @wyetthasspoken https://t.co/Z0T0HZhGpt
RT @cjbakermd: Ozempic, aka the "skinny jab" is all the rage, and makes a fortune for Novo Nordisk. But pancreatitis is no joke. Will it b…
RT @cjbakermd: Ozempic, aka the "skinny jab" is all the rage, and makes a fortune for Novo Nordisk. But pancreatitis is no joke. Will it b…
Ozempic, aka the "skinny jab" is all the rage, and makes a fortune for Novo Nordisk. But pancreatitis is no joke. Will it be Ozempic's undoing? GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/Xpo8MfuTfX
@HealthyFellow https://t.co/q8Uvj1oRyg
@IncJazzo @Frediculous https://t.co/x5IiTPKFhc I take Wegovy and my doctor was VERY clear on the types of food and amounts I should eat to avoid problems. I get blood work and check ups every few months to make sure kidneys, pancreas, thyroid, etc. are all still in normal range. This ain't no joke
Study: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/iAtQ26eolP
@davidcarr333 I’ve seen this exact case recently but… Data don’t show it… (Also agonist ;-)) https://t.co/uQdfY5z6wx
Use of #GLP1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis, bowel obstruction, and gastroparesis but not biliary disease. https://t.co/iS5OwrN5wd
Attending #IM2024? Supplement your schedule with Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss, from @JAMA_current. Free to read online during the meeting https://t.co/kVWgveEe8p https://t.co/u5sUw47CHm
Attending #IM2024? Supplement your schedule with Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss, from JAMA. Free to read online during the meeting https://t.co/iAuLgijsWz https://t.co/qxM5AjHkXu
RT @SUZUKI_WISE: @Toki_nd2525 おはようございます！ ほんとこれ大問題ですよねー。。 やめたらリバウンドなわけですし オゼンピックフェイス、PMDAの副作用救済制度からは外れますし。 https://t.co/GNL35elx03 https:…
@Toki_nd2525 おはようございます！ ほんとこれ大問題ですよねー。。 やめたらリバウンドなわけですし オゼンピックフェイス、PMDAの副作用救済制度からは外れますし。 https://t.co/GNL35elx03 https://t.co/vthq1ycPXP https://t.co/vdtpnHitvn https://t.co/qN2aIzIc7N
@simplyserotonin https://t.co/ikCVNz7uw2
@TeslaBoomerMama Careful! GLP-1 does have some nasty side effects and they are intentionally not finding them: https://t.co/SLhQ40ZEr8
Zdroj: Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023 Oct 5:e2319574. doi: 10.1001/jama.2023 https://t.co/VzD4O4YSEc
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroenterology | JAMA | JAMA Network https://t.co/5VTrQHCDX2
https://t.co/2oDf0dgpFF
OZEMPIC - Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/Bkn1QJuWbP
RT @orion7710: @gcfmd Although rare, there is an increased risk of pancreatitis, gastroparesis and bowel obstruction with GLP-1 receptor ag…
@gcfmd Although rare, there is an increased risk of pancreatitis, gastroparesis and bowel obstruction with GLP-1 receptor agonists. https://t.co/dEhDPNrea3
RT @gglinskii: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://t.co/OAAcoOYOW8
GLP-1使ってたことあるけど効果でずだった。体質によるだろうとは思ったので、しゃーなしと思っていた。 が、そんなことよりもリスクヤバすぎて使うのやめてよかったかもしれないという研究が。。 膵炎、胃不全麻痺、腸閉塞のリスク増加など消化器症状増えてるっぽい。。 https://t.co/d8IzQffLC5
【文献メモ】 Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/4F15BlBAPI
RT @gglinskii: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://…
RT @gglinskii: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://t.co/OAAcoOYOW8
RT @MMadkhali87: GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/bB638TZLrL
RT @MMadkhali87: GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/bB638TZLrL
GLP-1 Agonists and Gastrointestinal Adverse Events https://t.co/bB638TZLrL
malnutrition. Novo Nordisk is exploiting the corrupt US health care system to profit from Ozempic. 3/ https://t.co/dEhDPNrea3
https://t.co/daqqDoZY1f https://t.co/KJFA2Dt3OR
GLP-1作動薬のダイエットはもうやめようよ https://t.co/eiMYEivfQF
@Adtarie @ibamarief https://t.co/og8XCwuyGV
@Strategi_Bisnis Kl uang tdk jadi masalah boleh saja tetapi ingat juga resikonya : https://t.co/og8XCwuyGV
@Playm8z @Rimzzzeee Even the study acknowledges the difference in risk benefit analysis when you NEED vs when you don’t https://t.co/OBPWXXdIma https://t.co/PI3v3JPLaB
@jfcryan Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/pnLHrMWNr9
RT @FarmaMadridAP: (JAMA) aGLP1 y efectos gastrointestinales https://t.co/zIJXTdi7de
RT @FarmaMadridAP: (JAMA) aGLP1 y efectos gastrointestinales https://t.co/zIJXTdi7de
RT @FarmaMadridAP: (JAMA) aGLP1 y efectos gastrointestinales https://t.co/zIJXTdi7de
(JAMA) aGLP1 y efectos gastrointestinales https://t.co/zIJXTdi7de
$NVO $LLY $VKTX One would think as popularity increases, potentially a much bigger CAGR than already forecasted Gastroparesis Mkt by 2032 (8.2Bln). Poss, 4x bigger bcus of GLP-1 usage. $VNDA drug if approved becomes a blockbuster? https://t.co/fY7oubCST4 https://t.co/aSs85TqC3f
RT @docalok: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroente…
@sguyenet You can predict the adverse events of taking GLP-1 RA drugs by observing this. Gastroparesis and bowel obstruction? Bears litterally get a plug in their ass and don't shit for months while hibernating. https://t.co/ritgCrJCXP
https://t.co/nGm0Cl72PF
https://t.co/Jqklzft3Kp
@Biohazard3737 oops that was the write-up. Here is the study: https://t.co/ZfsVAz11a0
@DavidOCarpenter @JoeBiden Maybe we should wait for more research first before using a pill to reduce weight. https://t.co/zGeDqE6Sdu
RT @docalok: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroente…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroenterology | JAMA | JAMA Network https://t.co/xrVkRl66rU
「有害事象の発生頻度自体は低いとしても一定のリスクとなり得る」 https://t.co/9kxsxyuGVP
All GLP-1 receptor agonists, including Ozempic, Wegovy, Saxenda, Rybelsus (semaglutide), and Mounjaro (tirzepatide), have been linked to slower bowel transit times, thereby raising the risk of colorectal cancer, other bowel diseases https://t.co/yKxi6XgsoX https://t.co/Jls6ISEfN4
RT @NutrioSci: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_cur…
Compared with buprenorphine-naltrexone, use of GLP-1 receptor agonists for #obesity may increase the risk of pancreatitis, bowel obstruction and gastroparesis. @MohitSodhiUBC @JAMA_Current https://t.co/weQeaZAUIp
https://t.co/eXSCg7JzpI
減量目的のGLP-1作動薬で膵炎リスク9倍 https://t.co/uItCXwAAt2
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroenterology | JAMA | JAMA Network https://t.co/QOOKThgGXf
Usar remédios para diabetes, pensando no emagrecimento, traz algum risco? Fonte: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Imagens: https://t.co/h9MIFs9JLp https://t.co/Si6zI5Hmg9 https://t.co/8Ka6xVWGjD
RT @claymoreberserk: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Cl…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/za4AR2Atj5
ちなみに今回のデータはこの論文から↓↓ 【Article】 SODHI, Mohit, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 2023. https://t.co/D8cxjUcfI9
@yamamii_dokusho 論文中には経口・注射の区別についての記載はなかったように思いますよ～。これです！ ↓ SODHI, Mohit, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 2023. GLP-1 Agonists and Gastrointestinal Adverse
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
減量目的でのGLP-1受容体作動薬使用による消化器系有害事象リスクを評価。膵炎リスクが9倍に上昇するなど Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/6PxyDXWCzt
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
RT @Fizz_DI: 減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 20…
減量目的のGLP-1作動薬によるリスク 膵炎：HR=9.09 [95%CI: 1.25-66.00] 腸閉塞：HR=4.22 [95%CI: 1.02-17.40] 胃不全：HR=3.67 [95%CI: 1.15-11.90] JAMA . 2023 Oct 5:e2319574. Online ahead of print. PMID:37796527 https://t.co/bpOG8mLOMk
RT @muscle_penguin_: (282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGL…
RT @muscle_penguin_: (282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGL…
RT @docmaltese: ⚠️Risk of side effects associated with GLP-1RA therapy for weight loss via @JAMANetwork doi:10.1001/jama.2023.19574 ✅Panc…
RT @muscle_penguin_: (282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGL…
RT @muscle_penguin_: (282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGL…
(282/347) #論文マラソン 減量目的のGLP-1RAの副作用は？ 米国処方データベースを分析 リラグルチド 4144 人、セマグルチド 613 人、ブプロピオン ナルトレキソン(対照群) 654 人を分析 対照群と比べてGLP-RAは膵炎9.09倍、腸閉塞4.22倍のリスク。胆道疾患は関連無し https://t.co/MylAlvJyfr
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
『減量目的のGLP-1作動薬で膵炎リスク9倍』 ダイエット目的での糖尿病治療薬の使用はやめた方がいい 膵炎になっても保険適応での治療や副作用被害救済制度の対象外となる可能性もある https://t.co/X8H4SGsdHb
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/Lzz3fzjZjD
Top viewed in last 7 days in @JAMA_current 2️⃣ Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @UBC https://t.co/B9CCra1rkg https://t.co/AkGafgsugk
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @NutrioSci: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_cur…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | 减肥神药:司美格鲁肽, 或引发严重的胃肠道疾病风险. https://t.co/3fDbOeE9ER
GLP-1ダイエットと胃腸有害事象のリスク（JAMA） ✅膵炎、胃不全麻痺、腸閉塞のリスク増加と関連 ✅胆道疾患は関連なし ✅全体をまとめると有害事象は稀 https://t.co/zFMq0970gU
几乎每一个人，想“颜值”上镜直播 https://t.co/TGcpTn59F7
RT @NutrioSci: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_cur…
⚠️Risk of side effects associated with GLP-1RA therapy for weight loss via @JAMANetwork doi:10.1001/jama.2023.19574 ✅Pancreatitis ✅Gastroparesis ✅Bowel obstruction Lifestyle changes side effects? None... @Rcmsiow @ESPMco @DrMichaelSagner https://t.co/baDD6fybzu
The study was a research letter in JAMA https://jamanetwork.com/journals/jama/fullarticle/2810542 I've reproduced it here. The introduction states "Randomized trials examining efficacy of GLP-1 agonists for weight loss were not designed to capture these events due to small sample...
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/PjQRNnN9yT
RT @NutrioSci: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_cur…
RT @NutrioSci: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_cur…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_current #MedEd #obesity https://t.co/mCOHfQ2AVo https://t.co/T0LzOYmacy
@Jin_Sane https://t.co/CZSRNYg3xx
Use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone associated with increased risk of pancreatitis, gastroparesis & bowel obstruction. doi:10.1001/jama.2023.19574
RT @ph_adnan: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/Flu1A5Kbyy
RT @jlandreu2014: Nada como la adherencia a una dieta equilibrada y el ejercicio para perder peso. Los riesgos de Ozempic. Risk of Gastroin…
Nada como la adherencia a una dieta equilibrada y el ejercicio para perder peso. Los riesgos de Ozempic. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/QoEcrm2pvD
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network✅☑️✅☑️ https://t.co/NiomXvxLph
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. https://t.co/Iu5Wt0hOVR
@SBakerMD Here's the study you referred to: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/FclCkxhbxJ ........
RT @ShaojieChen1: #GLP1a Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss…
RT @ShaojieChen1: #GLP1a Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss…
#GLP1a Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss from Sodhi, @etminanm et al @JAMANetwork cited: https://t.co/XNPDyxxvzc @RichardAFerraro @FH_Verbrugge @mencardio @lFa1d @Ahmed43101178 @KSharmaMD https://t.co/lumIRQuuv4
Trend up+8: Sodhi M, ..., Etminan M (JAMA) __Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss__ https://t.co/RxqmTZmAVb
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/XDvxIG3Kiq
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network cc @kaopingchua https://t.co/hwi4TlPkNg
RT @EARL_med_tw:
Great feedback! Also now there are known severe digestive issues… https://t.co/PgDORViCHU https://t.co/IA8mWor3It
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss - it is good to see fast analysis using claim data to get a first clue to adverse events to then study them more https://t.co/CJlZdwZdaV
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
Drug discovery is never clean - your radar should immediately go up when told so…let’s see how this plays out…the GDP of some euro nations is at stake! Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA - JAMA Network [via @googlenews] https://t.co/DnEcyV0FGL https://t.co/QiGk9hm8D3
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA - JAMA Network https://t.co/mNlbCtooq0 https://t.co/RIqfJJ0kjg
RT @EARL_med_tw:
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
【JAMA 2023 Oct 5】 Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/OEuNPNFdlb
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
RT @zoeharcombe: More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Re…
More concerns about Ozempic/Wegovy... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss" https://t.co/svOtyp5yrZ
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/g2U5LnSprW
Sodhi et al: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss @JAMA_current https://t.co/uCm3A0TGsD
RT @syuichiao89: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://…
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://t.co/JdQaTSJvdC
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/s4RuJPObGM
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/5esV7aAXtF
A new study found that GLP-1 agonists, including Wegovy and Ozempic, are associated with an increased risk of serious medical conditions, including stomach paralysis, pancreatitis and bowel obstruction. https://t.co/s6IMeur0Cm https://t.co/9Szev3fWeO
F
CG
B
M